Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial.
Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Tijssen JGP, Piek JJ, de Winter RJ, Henriques JPS, Wykrzykowska JJ; Collaborators. Kraak RP, et al. EuroIntervention. 2020 Dec 4;16(11):e904-e912. doi: 10.4244/EIJ-D-18-00884. EuroIntervention. 2020. PMID: 31062692 Free article.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ. Kerkmeijer LSM, et al. EuroIntervention. 2022 Mar 18;17(16):1340-1347. doi: 10.4244/EIJ-D-21-00419. EuroIntervention. 2022. PMID: 34483094 Free PMC article. Clinical Trial.
Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients.
Elias J, van Dongen IM, Kraak RP, Tijssen RYG, Claessen BEPM, Tijssen JGP, de Winter RJ, Piek JJ, Wykrzykowska JJ, Henriques JPS. Elias J, et al. Among authors: kraak rp. Neth Heart J. 2017 Jul;25(7-8):429-438. doi: 10.1007/s12471-017-1008-x. Neth Heart J. 2017. PMID: 28612280 Free PMC article.
Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
Woudstra P, Grundeken MJ, Kraak RP, Hassell ME, Arkenbout EK, Baan J Jr, Vis MM, Koch KT, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP, Wykrzykowska JJ. Woudstra P, et al. Among authors: kraak rp. Am Heart J. 2014 Feb;167(2):133-40. doi: 10.1016/j.ahj.2013.09.017. Epub 2013 Oct 17. Am Heart J. 2014. PMID: 24439973 Free article. Clinical Trial.
Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography.
Grundeken MJ, Hassell ME, Kraak RP, de Bruin DM, Koch KT, Henriques JP, van Leeuwen TG, Tijssen JG, Piek JJ, de Winter RJ, Wykrzykowska JJ. Grundeken MJ, et al. Among authors: kraak rp. EuroIntervention. 2015 Dec;11(8):877-84. doi: 10.4244/EIJY14M08_15. EuroIntervention. 2015. PMID: 25169592 Free article.
Bioresorbable drug-eluting scaffolds for treatment of vascular disease.
Suwannasom P, Sotomi Y, Tateishi H, Tenekecioglu E, Zeng Y, Kraak RP, Wykrzykowska JJ, De Winter RJ, Serruys PW, Onuma Y. Suwannasom P, et al. Among authors: kraak rp. Expert Opin Drug Deliv. 2016;13(5):725-39. doi: 10.1517/17425247.2016.1153062. Epub 2016 Mar 1. Expert Opin Drug Deliv. 2016. PMID: 26865247 Review.
32 results